The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial
Open accessAbstract
Importance: Exenatide, a glucagon-like peptide 1 agonist used in type 2 diabetes, was recently found to have beneficial effects on motor function in a randomized, placebo-controlled trial in Parkinson disease (PD). Accumulating evidence suggests that impaired brain insulin and protein kinase B (Akt) signaling play a role in PD pathogenesis; however, exploring the extent to which drugs engage with putative mechnisms in vivo remains a challenge. Objective: To assess whether participants in the Exenatide-PD trial have augmented activity in brain insulin and Akt signaling pathways. Design, Setting, and Participants: Serum samples were collected from 60 participants in the single-center Exenatide-PD trial (June 18, 2014, to June 16, 2016), which compared patients with moderate PD randomized to 2 mg of exenatide once weekly or placebo for 48 weeks followed by a 12-week washout period. Serum extracellular vesicles, including exosomes, were extracted, precipitated, and enriched for neuronal source by anti-L1 cell adhesion molecule antibody absorption, and proteins of interest were evaluated using electrochemiluminescence assays. Statistical analysis was performed from May 1, 2017, to August 31, 2017. Main Outcomes and Measures: The main outcome was augmented brain insulin signaling that manifested as a change in tyrosine phosphorylated insulin receptor substrate 1 within neuronal extracellular vesicles at the end of 48 weeks of exenatide treatment. Additional outcome measures were changes in other insulin receptor substrate proteins and effects on protein expression in the Akt and mitogen-activated protein kinase pathways. Results: Sixty patients (mean [SD] age, 59.9 [8.4] years; 43 [72%] male) participated in the study: 31 in the exenatide group and 29 in the placebo group (data from 1 patient in the exenatide group were excluded). Patients treated with exenatide had augmented tyrosine phosphorylation of insulin receptor substrate 1 at 48 weeks (0.27 absorbance units [AU]; 95% CI, 0.09-0.44 AU; P = .003) and 60 weeks (0.23 AU; 95% CI, 0.05-0.41 AU; P = .01) compared with patients receiving placebo. Exenatide-treated patients had elevated expression of downstream substrates, including total Akt (0.35 U/mL; 95% CI, 0.16-0.53 U/mL; P < .001) and phosphorylated mechanistic target of rapamycin (mTOR) (0.22 AU; 95% CI, 0.04-0.40 AU; P = .02). Improvements in Movement Disorders Society Unified Parkinson's Disease Rating Scale part 3 off-medication scores were associated with levels of total mTOR (F4,50 = 5.343, P = .001) and phosphorylated mTOR (F4,50 = 4.384, P = .04). Conclusions and Relevance: The results of this study are consistent with target engagement of brain insulin, Akt, and mTOR signaling pathways by exenatide and provide a mechanistic context for the clinical findings of the Exenatide-PD trial. This study suggests the potential of using exosome-based biomarkers as objective measures of target engagement in clinical trials using drugs that target neuronal pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Herschkovitz, A., Liu, Y., Ilan, E., Ronen, D., Boura‐Halfon, S., & Zick, Y. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610949200 · Cited by 101
RetractedHughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Witwer, K. W., Buzás, E. I., Bemis, L. T., Bora, A., Lässer, C., Lötvall, J., Nolte‐‘t Hoen, E. N., Piper, M. G., Sivaraman, S., Skog, J., et al. (2013) · Journal of Extracellular Vesicles · doi:10.3402/jev.v2i0.20360 · Cited by 2,421
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123
Methodological Guidelines to Study Extracellular Vesicles
Coumans, F. A. W., Brisson, A. R., Buzas, E. I., Dignat-George, F., Drees, E. E. E., El-Andaloussi, S., Emanueli, C., Gasecka, A., Hendrix, A., Hill, A. F., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.309417 · Cited by 1,017
Fiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J. B., Abner, E. L., Petersen, R. C., Federoff, H. J., Miller, B. L., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.008 · Cited by 959
Self-citationPositive and negative regulation of insulin signaling through IRS-1 phosphorylation
Gual, P., Le Marchand-Brustel, Y., & Tanti, J.-F. (2005) · Biochimie · doi:10.1016/j.biochi.2004.10.019 · Cited by 912
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903
Exosomes are released by cultured cortical neurones
Fauré, J., Lachenal, G., Court, M., Hirrlinger, J., Chatellard-Causse, C., Blot, B., Grange, J., Schoehn, G., Goldberg, Y., Boyer, V., et al. (2006) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2005.12.003 · Cited by 896
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889 · cited 2×
“Patients and Study Design TheExenatide-PD trial (a randomized, double-blind, placebocontrolled, single center, 60-week trial of exenatide once weekly for the treatment of moderate-severity PD(43)) (NCT01971242)wasperformed fromJune 18, 2014, to June 16, 2016, to assess the effects of exenatide ondiseaseprogression for…”
BackgroundResultSelf-citationBomfim, T. R., Forny-Germano, L., Sathler, L. B., Brito-Moreira, J., Houzel, J.-C., Decker, H., Silverman, M. A., Kazi, H., Melo, H. M., McClean, P. L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57256 · Cited by 832
Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease
Shi, M., Liu, C., Cook, T. J., Bullock, K. M., Zhao, Y., Ginghina, C., Li, Y., Aro, P., Dator, R., He, C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1314-y · Cited by 676
Self-citationInsulin resistance in brain alters dopamine turnover and causes behavioral disorders
Kleinridders, A., Cai, W., Cappellucci, L., Ghazarian, A., Collins, W. R., Vienberg, S. G., Pothos, E. N., & Kahn, C. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500877112 · Cited by 486
Rapamycin Protects against Neuron Death in In Vitro and In Vivo Models of Parkinson's Disease
Malagelada, C., Jin, Z. H., Jackson-Lewis, V., Przedborski, S., & Greene, L. A. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3944-09.2010 · Cited by 462
Mustapic, M., Eitan, E., Werner, J. K., Berkowitz, S. T., Lazaropoulos, M. P., Tran, J., Goetzl, E. J., & Kapogiannis, D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00278 · Cited by 441
Self-citationCopp, J., Manning, G., & Hunter, T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3014 · Cited by 422
Exosomes: Vehicles for the Transfer of Toxic Proteins Associated with Neurodegenerative Diseases?
Bellingham, S. A., Guo, B. B., Coleman, B. M., & Hill, A. F. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00124 · Cited by 412
Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease
Goetzl, E. J., Kapogiannis, D., Schwartz, J. B., Lobach, I. V., Goetzl, L., Abner, E. L., Jicha, G. A., Karydas, A. M., Boxer, A., & Miller, B. L. (2016) · The FASEB Journal · doi:10.1096/fj.201600816r · Cited by 398
Self-citationCargo proteins of plasma astrocyte‐derived exosomes in Alzheimer's disease
Goetzl, E. J., Mustapic, M., Kapogiannis, D., Eitan, E., Lobach, I. V., Goetzl, L., Schwartz, J. B., & Miller, B. L. (2016) · The FASEB Journal · doi:10.1096/fj.201600756r · Cited by 386
Self-citationHigh complement levels in astrocyte‐derived exosomes of Alzheimer disease
Goetzl, E. J., Schwartz, J. B., Abner, E. L., Jicha, G. A., & Kapogiannis, D. (2018) · Annals of Neurology · doi:10.1002/ana.25172 · Cited by 370
Self-citationKapogiannis, D., Boxer, A., Schwartz, J. B., Abner, E. L., Biragyn, A., Masharani, U., Frassetto, L., Petersen, R. C., Miller, B. L., & Goetzl, E. J. (2015) · The FASEB Journal · doi:10.1096/fj.14-262048 · Cited by 345
Self-citationInsulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 328
Self-citationArnold, S. E., Lucki, I., Brookshire, B. R., Carlson, G. C., Browne, C. A., Kazi, H., Bang, S., Choi, B.-R., Chen, Y., McMullen, M. F., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.03.011 · Cited by 314
Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
Bassil, F., Fernagut, P.-O., Bezard, E., & Meissner, W. G. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.005 · Cited by 309
Stouffer, M. A., Woods, C. A., Patel, J. C., Lee, C. R., Witkovsky, P., Bao, L., Machold, R. P., Jones, K. T., de Vaca, S. C., Reith, M. E. A., et al. (2015) · Nature Communications · doi:10.1038/ncomms9543 · Cited by 286
Parkinson's disease, insulin resistance and novel agents of neuroprotection
Aviles-Olmos, I., Limousin, P., Lees, A., & Foltynie, T. (2013) · Brain · doi:10.1093/brain/aws009 · Cited by 283
Self-citationDiabetes and Risk of Parkinson’s Disease
Xu, Q., Park, Y., Huang, X., Hollenbeck, A., Blair, A., Schatzkin, A., & Chen, H. (2011) · Diabetes Care · doi:10.2337/dc10-1922 · Cited by 271
Selvaraj, S., Sun, Y., Watt, J. A., Wang, S., Lei, S., Birnbaumer, L., & Singh, B. B. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61332 · Cited by 245
Jakobsen, S. N., Hardie, D. G., Morrice, N., & Tornqvist, H. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100483200 · Cited by 238
Malagelada, C., Jin, Z. H., & Greene, L. A. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3928-08.2008 · Cited by 228
Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer’s Disease
Mullins, R. J., Diehl, T. C., Chia, C. W., & Kapogiannis, D. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00118 · Cited by 216
Self-citationWang, Q., Li, L., Xu, E., Wong, V., Rhodes, C., & Brubaker, P. L. (2004) · Diabetologia · doi:10.1007/s00125-004-1327-5 · Cited by 206
Ceriello, A., Novials, A., Ortega, E., Canivell, S., La Sala, L., Pujadas, G., Esposito, K., Giugliano, D., & Genovese, S. (2013) · Diabetes Care · doi:10.2337/dc12-2469 · Cited by 204
Diabetes and the Risk of Developing Parkinson’s Disease in Denmark
Schernhammer, E., Hansen, J., Rugbjerg, K., Wermuth, L., & Ritz, B. (2011) · Diabetes Care · doi:10.2337/dc10-1333 · Cited by 198
Irs1 Serine 307 Promotes Insulin Sensitivity in Mice
Copps, K. D., Hancer, N. J., Opare-Ado, L., Qiu, W., Walsh, C., & White, M. F. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2009.11.003 · Cited by 196
p38 MAPK and PI3K/AKT Signalling Cascades inParkinson's Disease.
Jha, S. K., Jha, N. K., Kar, R., Ambasta, R. K., & Kumar, P. (2015) · PubMed Central · Cited by 195
Long-Smith, C. M., Manning, S., McClean, P. L., Coakley, M. F., O’Halloran, D., Hölscher, C., & O’Neill, C. (2012) · NeuroMolecular Medicine · doi:10.1007/s12017-012-8199-5 · Cited by 168
Prospective Cohort Study of Type 2 Diabetes and the Risk of Parkinson's Disease
Driver, J. A., Smith, A., Buring, J. E., Gaziano, J. M., Kurth, T., & Logroscino, G. (2008) · Diabetes Care · doi:10.2337/dc08-0688 · Cited by 168
Insulin resistance impairs nigrostriatal dopamine function
Morris, J. K., Bomhoff, G. L., Gorres, B. K., Davis, V. A., Kim, J., Lee, P., Brooks, W. M., Gerhardt, G. A., Geiger, P. C., & Stanford, J. A. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.06.005 · Cited by 167
Neurodegeneration in an animal model of Parkinson’s disease is exacerbated by a high-fat diet
Morris, J. K., Bomhoff, G. L., Stanford, J. A., & Geiger, P. C. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00449.2010 · Cited by 163
Li, Y., Tweedie, D., Mattson, M. P., Holloway, H. W., & Greig, N. H. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06731.x · Cited by 154
Self-citationSharma, M. K., Jalewa, J., & Hölscher, C. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12469 · Cited by 151
Dopaminergic pathway reconstruction by Akt/Rheb‐induced axon regeneration
Kim, S. R., Chen, X. M., Oo, T. F., Kareva, T., Yarygina, O., Wang, C., During, M. J., Kholodilov, N. G., & Burke, R. E. (2011) · Annals of Neurology · doi:10.1002/ana.22383 · Cited by 145
Yu, H., Sun, T., An, J., Wen, L., Liu, F., Bu, Z., Cui, Y., & Feng, J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00086 · Cited by 137
Methods for extracellular vesicles isolation in a hospital setting
Sáenz-Cuesta, M., Arbelaiz, A., Oregi, A., Irizar, H., Osorio-Querejeta, I., Muñoz-Culla, M., Bañales, J. M., Falcón‐Pérez, J. M., Olascoaga, J., & Otaegui, D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00050 · Cited by 135
Wang, X., Zhai, Y., Xu, L., Qiao, C., Sun, X., Ding, J., Lu, M., & Hu, G. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.11.001 · Cited by 121
Insulin-degrading enzyme prevents α-synuclein fibril formation in a nonproteolytical manner
Sharma, S., Chorell, E., Steneberg, P., Vernersson-Lindahl, E., Edlund, H., & Wittung-Stafshede, P. E. (2015) · Scientific Reports · doi:10.1038/srep12531 · Cited by 119
Zhou, H., Li, D., Chen, S., Xin, T., Yang, J., Zhou, Y. Y., Hu, S., Tian, F., Wang, J., & Chen, Y. (2015) · Scientific Reports · doi:10.1038/srep12898 · Cited by 115
Zhou, Q., Liu, C., Liu, W., Zhang, H., Zhang, R., Liu, J., Zhang, J., Xu, C., Liu, L., Huang, S., et al. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu211 · Cited by 114
Insulin resistance and exendin-4 treatment for multiple system atrophy
Bassil, F., Canron, M., Vital, A., Bézard, E., Li, Y., Greig, N. H., Gulyani, S., Kapogiannis, D., Fernagut, P., & Meissner, W. G. (2017) · Brain · doi:10.1093/brain/awx044 · Cited by 114
Self-citationChoi, J., Jang, E.-H., Park, C., & Kang, J. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.12.008 · Cited by 112
Giraud, J., Leshan, R. L., Lee, Y.-H., & White, M. F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m308631200 · Cited by 104
Gao, S., Duan, C., Gao, G., Wang, X., & Yang, H. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.03.006 · Cited by 104
Choi, J., Park, C., & Jeong, J. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.11.022 · Cited by 103
JIANG, J., Jiang, J., Zuo, Y., & Gu, Z. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1280 · Cited by 101
A dual role for the cAMP-dependent protein kinase in tyrosine hydroxylase gene expression.
Kim, K. S., Park, D. H., Wessel, T. C., Song, B., Wagner, J. A., & Joh, T. H. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3471 · Cited by 101
Neuroendocrine abnormalities in Parkinson's disease
Pablo‐Fernández, E. D., Breen, D. P., Bouloux, P. M., Barker, R. A., Foltynie, T., & Warner, T. T. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314601 · Cited by 95
Self-citationXu, W., Yang, Y., Yuan, G., Zhu, W., Ma, D., & Hu, S. (2015) · Journal of Investigative Medicine · doi:10.1097/jim.0000000000000129 · Cited by 92
Candeias, E., Sebastião, I., Cardoso, S., Carvalho, C., Santos, M. S., Oliveira, C. R., Moreira, P. I., & Duarte, A. I. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0622-3 · Cited by 92
Mukai, E., Fujimoto, S., Sato, H., Oneyama, C., Kominato, R., Sato, Y., Sasaki, M., Nishi, Y., Okada, M., & Inagaki, N. (2010) · Diabetes · doi:10.2337/db10-0021 · Cited by 90
Gao, H., Zeng, Z., Zhang, H., Zhou, X., Guan, L., Deng, W., & Xu, L. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00505 · Cited by 83
Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease
Morris, J. K., Zhang, H., Gupte, A. A., Bomhoff, G. L., Stanford, J. A., & Geiger, P. C. (2008) · Brain Research · doi:10.1016/j.brainres.2008.08.089 · Cited by 83
Jones, K. T., Woods, C., Zhen, J., Antonio, T., Carr, K. D., & Reith, M. E. A. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13930 · Cited by 83
Akt as a Victim, Villain and Potential Hero in Parkinson’s Disease Pathophysiology and Treatment
Greene, L. A., Levy, O., & Malagelada, C. (2011) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9671-8 · Cited by 79
Targetting Exosomes as a New Biomarker and Therapeutic Approach for Alzheimer’s Disease
Yin, Q., Ji, X., Lv, R., Pei, J.-J., Du, Y., Shen, C., & Hou, X. (2020) · Clinical Interventions in Aging · doi:10.2147/cia.s240400 · Cited by 79
Degeneration of Dopaminergic Neurons Due to Metabolic Alterations and Parkinson’s Disease
Song, J., & Kim, J. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00065 · Cited by 75
Mansur, R. B., Delgado‐Peraza, F., Subramaniapillai, M., Lee, Y. L., Iacobucci, M., Rodrigues, N. B., Rosenblat, J. D., Brietzke, E. M., Cosgrove, V. E., Kramer, N. E., et al. (2020) · Cells · doi:10.3390/cells9040895 · Cited by 73
Self-citationExendin-4 promotes proliferation and differentiation of MC3T3-E1 osteoblasts by MAPKs activation
Feng, Y., Su, L., Zhong, X., Guohong, W., Xiao, H., Li, Y., & Xiu, L. (2015) · Journal of Molecular Endocrinology · doi:10.1530/jme-15-0264 · Cited by 65
Self-citationBrain GLP-1 and insulin sensitivity
Sandoval, D. A., & Sisley, S. R. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.02.017 · Cited by 58
Eitan, E., Tosti, V., Suire, C. N., Cava, E., Berkowitz, S., Bertozzi, B., Raefsky, S. M., Veronese, N., Spangler, R., Spelta, F., et al. (2017) · Aging Cell · doi:10.1111/acel.12657 · Cited by 56
Self-citationExendin-4 improved rat cortical neuron survival under oxygen/glucose deprivation through PKA pathway
Wang, M., Huang, Y., Zhang, G.-P., Mao, L., Xia, Y., Mei, Y.-W., & Hu, B. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.025 · Cited by 51
Sekar, S., & Taghibiglou, C. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.12.049 · Cited by 49
Bader, M., Li, Y., Tweedie, D., Shlobin, N. A., Bernstein, A., Rubovitch, V., Tovar‐y‐Romo, L. B., DiMarchi, R. D., Hoffer, B. J., Greig, N. H., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00356 · Cited by 49
Self-citationBaladi, M. G., Horton, R. E., Owens, W. A., Daws, L. C., & France, C. P. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv024 · Cited by 48
Yu, Y.-W., Hsieh, T.-H., Chen, K., Wu, J. C.-C., Hoffer, B. J., Greig, N. H., Li, Y., Lai, J.-H., Chang, C., Lin, J., et al. (2016) · Journal of Neurotrauma · doi:10.1089/neu.2015.4229 · Cited by 41
Self-citationRodríguez‐Blanco, J., Martín, V., García‐Santos, G., Herrera, F., Zapico, S. C., Antolín, I., & Rodríguez, C. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23066 · Cited by 39
Yue, P., Gao, L., Wang, X., Ding, X., & Teng, J. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2184-1 · Cited by 35
Exendin-4 Promotes Beta Cell Proliferation via PI3k/Akt Signalling Pathway
Wang, C., Chen, X., Ding, X., He, Y., Gu, C., & Zhou, L. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000374027 · Cited by 34
Yang, Y., Ma, D., Xu, W., Chen, F., Du, T., Yue, W., Shao, S., & Yuan, G. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.10.005 · Cited by 32
Singh, S., Mishra, A., Mishra, S. K., & Shukla, S. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.05.017 · Cited by 31
Kim, S. R., Ries, V., Cheng, H., Kareva, T., Oo, T. F., Yu, W. H., Duff, K., Kholodilov, N. G., & Burke, R. E. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.07.003 · Cited by 27
Chalorak, P., Dharmasaroja, P., & Meemon, K. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00303 · Cited by 23
Zheng, A., Cao, L., Qin, S., Chen, Y., Li, Y., & Zhang, D. (2016) · Heart Lung and Circulation · doi:10.1016/j.hlc.2016.07.006 · Cited by 15
Self-citation
Cited by
Progress towards therapies for disease modification in Parkinson's disease
Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R., & Foltynie, T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00061-2 · Cited by 419
Self-citationEfficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Self-citationLiu, X., Zhao, S., Tan, L., Tan, Y., Wang, Y., Ye, Z., Hou, C., Xu, Y., Liu, S., & Wang, G. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113932 · Cited by 286
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
Metadata
- Authors
- Athauda, D., Gulyani, S., Karnati, H. K., Li, Y., Tweedie, D., Mustapic, M., Chawla, S., Chowdhury, K., Skene, S. S., Greig, N. H., Kapogiannis, D., & Foltynie, T.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2019-04-01
- Volume
- 76
- Issue
- 4
- Pages
- 420
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2908881986
- Cited by
- 258
- References
- 84
- FWCI
- 18.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.